Featured Research

from universities, journals, and other organizations

Popular anti-platelet therapy reduces risk of cardiovascular events in men and women

Date:
November 15, 2009
Source:
American College of Cardiology
Summary:
A new study adds to a growing body of research seeking to evaluate and understand possible sex differences associated with anti-platelet therapies.

A new study, published in the November 17, 2009, issue of the Journal of the American College of Cardiology, adds to a growing body of research seeking to evaluate and understand possible sex differences associated with antiplatelet therapies. This study -- the first to look at the impact of clopidogrel, one of the most frequently prescribed drugs to prevent and treat heart disease, in women -- found it to be effective in reducing cardiovascular (CV) events in both men and women with no statistically significant sex differences in terms of expected clinical benefit or increased harm.

Clopidogrel reduced cardiovascular events by 16 percent in men compared to 7 percent in women; however, this difference was not statistically significant. Although there was a clear reduction in the risk of CV events in both sexes, women derived the most benefit from a decrease in their risk of heart attack with a nonsignificant reduction in stroke and total death. Data show a small, but real excess risk of major bleeding with clopidogrel therapy in both men and women; adding clopidogrel to aspirin therapy resulted in a 43 percent and 21 percent increased risk of major bleeding in women and men, respectively.

According to the authors, by treating 1,000 men and 1,000 women with clopidogrel on a background of aspirin for an average of eight months, clinicians can prevent eight cardiovascular events in women and 12 in men; from a safety perspective, there would be five major bleeding incidents in women and two in men.

Researchers performed a meta-analysis of five major clinical trials to evaluate the clinical benefit and risk of this antiplatelet therapy in women and men and determine whether there are sex-based differences in treatment response. Nearly 80,000 individuals with a broad range of CV diseases were enrolled in these trials, 30 percent of whom were women. Lead investigators of the five double-blinded, randomized placebo-controlled trials shared original study data with authors.

Clopidogrel works to disrupt platelet activity and prevents them from clotting and causing heart attacks and strokes. It is typically used in patients with heart attacks, those at increased severity of angina, and in patients following stent implantation. It is also commonly used in those with established CV disease.

Women have traditionally been underrepresented in clinical trials enrollment. As newer, more potent platelet therapies are being developed, it will be important to continue to examine whether sex differences exist in the therapeutic effect of these drugs. According to the accompanying editorial, research to examine the impact of sex on responses to cardiovascular treatment should be ongoing, especially as the decrease in deaths related to heart disease has been less for women and has actually increased in women younger than 55 years of age since 1980 despite progress in reducing associated morbidity and mortality.


Story Source:

The above story is based on materials provided by American College of Cardiology. Note: Materials may be edited for content and length.


Cite This Page:

American College of Cardiology. "Popular anti-platelet therapy reduces risk of cardiovascular events in men and women." ScienceDaily. ScienceDaily, 15 November 2009. <www.sciencedaily.com/releases/2009/11/091109173610.htm>.
American College of Cardiology. (2009, November 15). Popular anti-platelet therapy reduces risk of cardiovascular events in men and women. ScienceDaily. Retrieved September 21, 2014 from www.sciencedaily.com/releases/2009/11/091109173610.htm
American College of Cardiology. "Popular anti-platelet therapy reduces risk of cardiovascular events in men and women." ScienceDaily. www.sciencedaily.com/releases/2009/11/091109173610.htm (accessed September 21, 2014).

Share This



More Health & Medicine News

Sunday, September 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com
Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins